Literature DB >> 10674654

Proinflammatory cytokine mRNA responses in experimental Burkholderia pseudomallei infection in mice.

G C Ulett1, N Ketheesan, R G Hirst.   

Abstract

Melioidosis is a potentially fatal disease of both human and animals caused by the bacterium Burkholderia pseudomallei. Disease is endemic in tropical and subtropical regions of Southeast Asia and Northern Australia. The pathogenesis of melioidosis is poorly understood. In particular, the host responses that occur following infection, and the specific host-pathogen interactions that result in the development of either acute or chronic infection are unclear. Using an established murine model, we investigated early proinflammatory cytokine responses believed to be critical in the development of acute and chronic B. pseudomallei infection. Semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) was used to assess levels of mRNA for tumor necrosis factor-alpha (TNF-alpha), interleukin 1beta (IL-1beta) and interleukin 6 (IL-6) in the liver of mice following infection. We demonstrate that the level of mRNA for these cytokines increase moderately in chronic infection in C57BL/6 mice. However, in acute infection in BALB/c mice, mRNA responses for these cytokines were shown to be comparatively greater. These results demonstrate that early proinflammatory cytokine responses are important in the immunopathogenesis of melioidosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10674654     DOI: 10.1016/s0001-706x(99)00075-3

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  18 in total

Review 1.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

2.  Cytokine gene expression in innately susceptible BALB/c mice and relatively resistant C57BL/6 mice during infection with virulent Burkholderia pseudomallei.

Authors:  G C Ulett; N Ketheesan; R G Hirst
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

3.  Impaired early cytokine responses at the site of infection in a murine model of type 2 diabetes and melioidosis comorbidity.

Authors:  Kelly A Hodgson; Brenda L Govan; Anna K Walduck; Natkunam Ketheesan; Jodie L Morris
Journal:  Infect Immun       Date:  2012-12-03       Impact factor: 3.441

4.  Burkholderia pseudomallei induces IL-23 production in primary human monocytes.

Authors:  Panthong Kulsantiwong; Matsayapan Pudla; Jitrada Boondit; Chanthiwa Wikraiphat; Susanna J Dunachie; Narisara Chantratita; Pongsak Utaisincharoen
Journal:  Med Microbiol Immunol       Date:  2015-11-12       Impact factor: 3.402

5.  Murine pulmonary infection and inflammation induced by inhalation of Burkholderia pseudomallei.

Authors:  T Eoin West; Nicolle D Myers; H Denny Liggitt; Shawn J Skerrett
Journal:  Int J Exp Pathol       Date:  2012-12       Impact factor: 1.925

6.  Genome wide transcriptome profiling of a murine acute melioidosis model reveals new insights into how Burkholderia pseudomallei overcomes host innate immunity.

Authors:  Chui-Yoke Chin; Denise M Monack; Sheila Nathan
Journal:  BMC Genomics       Date:  2010-11-27       Impact factor: 3.969

7.  Evaluation of surrogate animal models of melioidosis.

Authors:  Jonathan Mark Warawa
Journal:  Front Microbiol       Date:  2010-12-29       Impact factor: 5.640

8.  Defense Mechanisms of Hepatocytes Against Burkholderia pseudomallei.

Authors:  Antje Bast; Imke H E Schmidt; Paul Brauner; Bettina Brix; Katrin Breitbach; Ivo Steinmetz
Journal:  Front Microbiol       Date:  2012-01-10       Impact factor: 5.640

9.  Immunogenic recombinant Burkholderia pseudomallei MprA serine protease elicits protective immunity in mice.

Authors:  Chui-Yoke Chin; Swee-Chen Tan; Sheila Nathan
Journal:  Front Cell Infect Microbiol       Date:  2012-06-15       Impact factor: 5.293

Review 10.  Development of Burkholderia mallei and pseudomallei vaccines.

Authors:  Ediane B Silva; Steven W Dow
Journal:  Front Cell Infect Microbiol       Date:  2013-03-11       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.